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Objectives We used a murine model of arrhythmogenic right ventricular cardiomyopathy (ARVC) to test whether reducing
ventricular load prevents or slows development of this cardiomyopathy.
Background At present, no therapy exists to slow progression of ARVC. Genetically conferred dysfunction of the mechanical
cell–cell connections, often associated with reduced expression of plakoglobin, is thought to cause ARVC.
Methods Littermate pairs of heterozygous plakoglobin-deficient mice (plako/–) and wild-type (WT) littermates underwent
7 weeks of endurance training (daily swimming). Mice were randomized to blinded load-reducing therapy (furo-
semide and nitrates) or placebo.
Results Therapy prevented training-induced right ventricular (RV) enlargement in plako/– mice (RV volume: untreated
plako/– 136  5 l; treated plako/– 78  5 l; WT 81  5 l; p  0.01 for untreated vs. WT and untreated
vs. treated; mean  SEM). In isolated, Langendorff-perfused hearts, ventricular tachycardias (VTs) were more
often induced in untreated plako/– hearts (15 of 25), than in treated plako/– hearts (5 of 19) or in WT hearts
(6 of 21, both p  0.05). Epicardial mapping of the RV identified macro–re-entry as the mechanism of ventricu-
lar tachycardia. The RV longitudinal conduction velocity was reduced in untreated but not in treated plako/–
mice (p  0.01 for untreated vs. WT and untreated vs. treated). Myocardial concentration of phosphorylated con-
nexin43 was lower in plako/– hearts with VTs compared with hearts without VTs and was reduced in untreated
plako/– compared with WT (both p  0.05). Plako/– hearts showed reduced myocardial plakoglobin concen-
tration, whereas -catenin and N-cadherin concentration was not changed.
Conclusions Load-reducing therapy prevents training-induced development of ARVC in plako/– mice. (J Am Coll Cardiol
2011;57:740–50) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.09.046Arrhythmogenic right ventricular cardiomyopathy (ARVC) is
an important cause of sudden death in young athletes (1–5).
ysfunction of the mechanical cell-cell junction seems to play
central role in ARVC: mutations in genes encoding the
echanical cell-cell contact proteins plakophilin-2, plakoglo-
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February 8, 2011:740–50 Load-Reducing Therapy Prevents ARVCspecial junctions of the area composita (constituting 90% of
the intercalated disk area), which consists of desmosomal and
fascia adherens components (13,14).
Transgenic mouse models have verified the biological rele-
vance of mechanical cell–cell contact dysfunction for ARVC:
heterozygous deletion of plakoglobin is sufficient to provoke an
ARVC phenotype comprising right ventricular (RV) enlarge-
ment and dysfunction and inducible ventricular tachycardias
(VTs) without cardiac fibro-fatty infiltration (15). Heterozy-
gous deletion of desmoplakin causes a biventricular cardio-
myopathy with myocardial deposition of fat and fibrous
tissue (16), and transgenic expression of desmoglein causes
biventricular myocardial necrosis (17). Recent analyses in
myocardial tissue from ARVC patients extend these find-
ings and suggest that reduced immunohistological plako-
globin light intensity might be a sensitive and specific marker
for ARVC in patients (4).
Despite progress in the prevention of sudden cardiac
death in ARVC patients by antiarrhythmic drugs and
implanted defibrillators (18,19), there is at present no
treatment available that slows or prevents development of
the disease (1,20,21). Clinical observations suggest that
endurance training, especially when performed at a compet-
itive level, might accelerate the manifestation of ARVC in
susceptible individuals (22), and current recommendations
suggest that ARVC patients should abstain from high-level
sports activity (23). Likewise, endurance training can accel-
erate the development of ARVC in heterozygous
plakoglobin-deficient mice (plako/–) (15), suggesting that
hronically increased volume load might contribute toFigure 1 Flow Chart of the Study Protocolevelopment of ARVC in sus-
eptible patients. Therefore, we
ested whether reducing ventric-
lar pressure and volume load
an prevent or slow training-
nduced development of ARVC.
ethods
nimal model and study design.
e studied young adult plako/–
mice and their wild-type (WT)
littermates (15). After a baseline
echocardiography, all mice under-
went 7 weeks of endurance train-
ing by daily swimming, initiated
at 5 min/day and increased to
90-min/day swimming duration
(15). Mice were randomized to a load-reducing therapy
consisting of the loop diuretic furosemide (4 mg/kg/day
continuous treatment) and nitrates (isosorbide dinitrate 20
mg/kg for 15 h/day alternating with molsidomine 8 mg/kg
for 9 h/day to avoid nitrate tolerance) (24) or to sham
therapy (water) (Fig. 1). These agents were chosen because
they are clinically available and reduce ventricular load:
chronic therapy with nitrates lowers RV pressure (24,25),
and furosemide reduces pulmonary capillary wedge pressure
and volume load (24,25).
All drugs were administered via drinking water. Individ-
ual daily water intake was monitored, and drug concentra-
Abbreviations
and Acronyms
ARVC  arrhythmogenic
right ventricular
cardiomyopathy
Cx43  connexin43
PCR  polymerase chain
reaction
P-Cx43  phosphorylated
connexin43
plako/–  heterozygous
plakoglobin-deficient mice
RV  right ventricular
VT  ventricular
tachycardia
WT  wild-type
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Therapy was well-tolerated and reduced blood pressure,
measured as mean of 5 tail-cuff measurements/mouse on 2
independent occasions (n  6 mice, mean  SEM), from
98  2/66  1 mm Hg (mean pressure 77  1 mm Hg) to
87  5/60  3 mm Hg (mean pressure 69  3 mm Hg,
 0.05). Therapy also reduced RV pressure measured as
aximal trans-pulmonary Doppler flow velocity from 2.8
.3 m/s to 2.3  0.2 m/s (18% difference, n  13 mice,
 0.03, mean  SEM, all measurements performed
uring light sedation).
After training, follow-up echocardiography was per-
ormed; hearts were isolated for electrophysiological studies
nd immediately shock-frozen or fixated in formalin for
rotein chemistry and histological studies. All functional
ests were blinded to genotype and therapy.
chocardiography. All mice underwent echocardiography
VEVO 770 and 2100, Visualsonics, Toronto, Ontario,
anada, or HP5500, Philips Medical Systems, Andover,
assachusetts) during light sedation (oxygenated isoflurane
.5% by inhalation) following validated protocols for left
entricular (LV) and RV size and function (15).
lectrophysiological studies. Mice were anesthetized
urethane 2 g/kg bodyweight IP) and heparinized, and their
earts were excised. Preparation time was between 3:00 and
:30 min from excision of the heart to initiation of perfusion
n a modified Langendorff apparatus (15,26,27). A 2-F
ctapolar catheter (interelectrode distance 500 m) was
nserted through the tricuspid orifice into the RV, and a
47-point multielectrode (13  19 grid, interelectrode
istance 300 m) was positioned over either the RV or LV.
The heart was stimulated from the center of the multi-
electrode or from the tip of the octapolar catheter at twice
Echocardiographic Parameters in Heterozygous Plako/– and WT MBef re and After Training Without and With Pre-Lo d–Reducing heTable 1 Echo ardiographic Parameters in Heterozygo s Plako

Before and After Training Without and With Pre-Load–R
Before Training (7 Weeks)
WT Pla
Sham
(n  10)
Treated
(n  11)
Sham
(n  29)
Heart rate (beats/min) 427 3 423 3 425 2
RV parameters
RV area 4-chamber view, mm2 5.4 0.4 5.3 0.4 5.3 0.3
RV area long-axis view, mm2 3.8 0.3 4.0 0.3 3.9 0.2
RV area short-axis view, mm2 3.7 0.3 3.9 0.3 3.9 0.2
RV diastolic volume (l) 64 1 66 1 68 0
LV parameters
LV end-diastolic diameter (mm) 3.69 0.07 3.66 0.07 3.68 0.05
LV end-systolic diameter (mm) 1.99 0.06 1.99 0.04 1.96 0.03
LV fractional shortening (%) 46 1 46 1 47 1
Cardiac output (ml/min) 9.7 0.5 8.8 0.4 9.1 0.4
LV mass (mg) 80 4 80 4 81 3
Values are mean  SEM. Echocardiographic parameters in heterozygous plakoglobin-deficient (
(Sham/Treated). *p 0.05 before versus after training (paired t test); †p 0.05 untreated plako/
ll information is given for paired measurements before and after therapy. Data are expressed as
RV  right ventricular; LV  left ventricular.diastolic threshold with steady-state pacing at 100-ms cyclelength or an 8-pulse drive train at a pacing cycle-length of
100 ms followed by a single premature stimulus. The
coupling interval of the premature stimulus started at 60 ms
and was reduced in steps of 2 ms until the effective
refractory period was reached.
Unipolar electrograms from the multielectrode were re-
corded at a 2-kHz sampling rate. The metal aortic cannula
was used as reference. Signals were analyzed with a custom-
made analysis program and manually validated (28). The
time of maximal negative dV/dt in the QRS complex in the
unipolar electrograms was defined as local activation. Sus-
tained VT was defined as either monomorphic VT of more
than 1-s duration or any arrhythmia requiring defibrillation
or termination of the experiment. We counted spontaneous
arrhythmias and arrhythmias induced by a single RV extra
stimulus (15).
Western blots. Hearts were snap-frozen in liquid nitrogen.
Left ventricular tissue was homogenized (3,000 rpm, 45 s)
with Mikro-Dismembrator S (Sartorius) and resuspended
in lysis buffer (50 mmol/l tris(hydroxymethyl)amino meth-
ane pH 7.4, 150 mmol/l sodium chloride, 0.5% Triton-X-
100), supplemented with a protease inhibitor cocktail tablet
(Complete Mini, Roche, Indianapolis, Indiana). Homoge-
nates were centrifuged (2,500 rpm, 5 min). Total protein
lysate (30 g) was loaded onto a 12% sodium dodecyl
sulfate–polyacrylamide resolving gel (1-mm-thick) and elec-
trophoresed (60 min, 200 V). Gels were blotted to a
nitrocellulose membrane (Protran, Whatman, Piscataway,
New Jersey) by means of a wet transfer system (60 min,
100 V). Membranes were incubated overnight at 4°C with
mouse-derived anti-plakoglobin (BD TL [BD Transduc-
tion Laboratories, San Jose, California] clone 15, 1:2,000),
anti--catenin (BD TL clone 14, 1:1,000), anti-N-cadherin
d WT Mice
ing Therapy
After Training (15 Weeks)
WT Plako/–
Treated
n  26)
Sham
(n  10)
Treated
(n  11)
Sham
(n  29)
Treated
(n  26)
7 2 422 4 425 3 422 3 428 3
.4 0.3 5.7 0.5* 6.0 0.3* 8.8  0.3†‡ 5.9 0.2*
.9 0.2 4.3 0.3* 4.5 0.2* 6.4  0.2†‡ 4.4 0.1*
.9 0.2 4.1 0.3* 4.2 0.3* 6.1  0.2†‡ 4.2 0.2*
6 0 76 1* 78 1* 138  1†‡ 78 0*
9 0.04 3.91 0.06* 3.85 0.07* 3.90 0.04* 3.85 0.04*
5 0.02 2.09 0.05* 2.08 0.04* 2.10 0.03* 2.06 0.03*
6 1 47 1 46 1 46 0 46 0
.1 0.4 10.1 0.4 10.0 0.5* 10.8 0.5* 10.3 0.5*
5 2 105 5* 102 3* 105 2* 99 2*
–) and wild-type (WT) mice before and after training without and with preload-reducing therapy
WTmice; ‡p 0.05 untreated versus treated plako/– mice (bold numbers, analysis of variance).
 SEM.icerapy/– an
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ko/–
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February 8, 2011:740–50 Load-Reducing Therapy Prevents ARVCdehydrogenase (Ambion, AM4300, 1:20,000). The mem-
branes were then incubated with the polyclonal rabbit
anti-mouse Ig, HRP-linked, secondary antibody (Dako,
1 h). Detection was performed with ECL plus (GE Health-
care, Amersham, Piscataway, New Jersey).
Membrane proteins were isolated (29). Protein (50 g)
was added to a 12% sodium dodecyl sulfate–polyacrylamide
resolving gel (1-mm-thick) and electrophoresed (75 min,
160 V). Gels were blotted to a pre-equilibrated PVDF
membrane (Immobilon-P, Millipore, Bedford, Massachu-
Figure 2 Training-Induced RV Enlargement Is Prevented by Pre
(A) Representative echocardiographic long-axis views of the heart of 4 mice after
(treated WT), heterozygous plakoglobin-deficient mouse without therapy (plako/–)
indicated by arrows. (B) Mean RV volume in the 4 study groups. Training increase
given as mean  SEM.setts) by means of a semi-dry system (60 min, 12 V, 500 pmA). Post-blot membrane was incubated with rabbit-
derived anti-calnexin (1:2000 dilution in block buffer) or
pan-cadherin (rabbit polyclonal, Sigma C3678, Sigma, St.
Louis, Missouri) and anti-connexin43 (Cx43) rabbit-
derived primary antibody (1:800 dilution in block buffer, 4 h
each), anti-plakoglobin antibody (mouse monoclonal clone
PG 5.1, Progen #61005, Progen Biotechnik, Heidelberg,
Germany), or anti--catenin antibody (BD mouse mono-
lonal, #610153) antibodies.
mmunohistology. Immunofluorescence microscopy was
educing Therapy in Heterozygous Plako/– Mice
nce training: wild-type mouse without therapy (WT), treated wild-type mouse
reated plako/– mouse (treated plako/–). Right ventricular (RV) diameters are
ize in untreated plako/– mice, therapy prevented RV enlargement. All dataload-R
endura
, and t
d RV serformed as described (13,14). We used monoclonal anti-
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Load-Reducing Therapy Prevents ARVC February 8, 2011:740–50bodies specific for desmoplakin (murine mAb, clone
DP447, Progen Biotechnik), -catenin (rabbit antibodies,
igma, Taufkirchen, Germany), plakoglobin (murine AB,
lone PG 5.1., Progen Biotechnik), and plakophilin-2
murine mAB, mix of clones PP2/62, PP2/86, and PP2/
50, Progen Biotechnik).
Immunohistochemistry was performed on freshly fixed
eart tissue with a monoclonal mouse anti-Cx43 antibody
Chemicon #3067, 1:250, Chemicon, Temecula, Califor-
Figure 3 Inducibility of Macro–Re-Entrant VTs Is Prevented by
(A) Tracing (top) and activation map (bottom) of a polymorphic ventricular tachyca
(S2, coupling interval 30 ms) at the RV epicardium. Colors show scale activation t
inhomogeneous activation pattern showing functional conduction block. Activation
ter and left of the electrode grid. In the map of the S2 activation of the first beat o
occurred more often in untreated than in treated plako/– or WT mouse hearts. Gia) and a biotin-labeled goat anti-mouse IgG (Santa Cruz Piotechnology, Santa Cruz, California) followed by visual-
zation with peroxidase-coupled streptavidin and 4=,6-
iamidino-2-phenylindole. Nuclei were counterstained with
ematoxylin.
uantitative polymerase chain reaction (PCR). Total
ibonucleic acid isolated from hearts of plako/–, embryonal
plako-/-, and WT hearts was reverse transcribed with the
ulti-Scribe RT kit (Applied Biosystems, Carlsbad, Cali-
ornia) and random hexamers. Subsequently, quantitative
ad-Reducing Therapy in Trained Plako/– Mouse Hearts
VT) in a trained, untreated plako/– mouse after a single premature stimulus
nes indicate 2-ms isochrones. The single premature stimulus was followed by an
around the area of activation block (thick black line) and re-entered at the cen-
VT, the same isochrones appear in the left upper corner. (B) Sustained VTs
 glyceraldehyde-3-phosphate dehydrogenase; other abbreviations as in Figure 2.Prelo
rdia (
ime, li
circled
f the
APDHCRs were conducted in triplicate with SYBR-Green I
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tary deoxyribonucleic acid as template in a Stratagene
Mx3000P cycler (Stratagene, Amsterdam, the Nether-
lands). Relative expression compared with WT tissue was
calculated with the Ct method. Two housekeeping genes
(hypoxanthine phosphoribosyltransferase 1 and 60S acidic
ribosomal protein PO) were assayed. Intron-spanning gene-
specific primers were designed with the Primer3 software (30).
Statistical analysis. Values are shown as mean  SEM.
One-way analysis of variance followed by a Holm-Sidak test to
correct for multiple group testing was used to compare numer-
ical parameters between study groups. Paired t test was used to
assess the effect of therapy on numerical parameters within
each group. Because there was no effect of therapy on cardiac
size or function in WT mice, we combined WT measurements
for most of the tissue analyses. Categorical variables were
compared by Fisher exact test. A statistical significance was
assumed at a 2-sided p  0.05.
Results
Load-reducing therapy prevents RV enlargement and
induction of VTs in trained plako/– mice. Training
caused mild LV hypertrophy without altering LV function
in both WT and plako/– mice (Table 1). Training slightly
ffected RV parameters in WT mice and treated plako/–
mice but markedly increased RV size in untreated plako/–
mice (Fig. 2, Table 1) (compare Kirchhof et al. [15]).
lthough therapy completely prevented training-induced
V enlargement (Fig. 2, Table 1), training-induced LV
hypertrophy was not affected (Table 1).
In isolated beating perfused hearts, sustained VTs oc-
curred more often in untreated plako/– hearts than in
reated plako/– hearts or WT hearts (Fig. 3). Mean cycle
length of VTs was 46  3 ms in untreated plako/– hearts
(n  11), 44  3 ms in treated plako/– hearts (n  7), and
Electrophysiological Parameters of WT, Trained Trand Trained Untreated Het ozygous Plako/–Table 2 Electrophysiological Parameters of Wand Trained Untreated Heterozygo
WT
RV longitudinal CV S1 (cm/s) 53.1
RV longitudinal CV S2  50 ms (cm/s) 50.4
RV transversal CV (cm/s) 30.8
RV transversal CV S2  50 ms (cm/s) 26.3
RV ERP (ms) 38
LV longitudinal CV (cm/s) 55.6
LV transversal CV (cm/s) 29.2
LV ERP (ms) 47
ERP RV catheter (ms) 37
VT-induced during RV pacing 6/21 (2
VT-induced during LV pacing 1/19 (5
Values are mean SD or n (%). Electrophysiological parameters of WT
plako/– mice. Data expressed as mean SEM. *p 0.001 versus W
versus treated plako/– mice (red numbers).
CV  conduction velocity in cm/s; ERP  effective refractory perio
applying a single extra stimulus at 50-ms coupling interval; VT  sust37  2 ms in WT hearts (n  7, p  0.02 for WT vs. all dlako/– hearts combined). Premature stimulation from the
V (i.e., from a site distant to the suspected pathology)
arely resulted in sustained VTs in either group (27).
ffective refractory periods were not statistically different
etween study groups (Table 2). Induction of VTs was
ssociated with functional conduction block and macro-
eentry in untreated plako/– hearts (example in Fig. 3,
upper panels). To further investigate whether anatomic
factors (enlargement of the RV) or functional effects (con-
duction slowing in RV myocardium) caused prolongation of
activation, high-density ventricular activation maps during
pacing from the center of the multielectrode were recon-
structed and conduction velocities were computed. Longi-
tudinal RV conduction velocity was reduced in untreated
plako/– compared with treated plako/– or WT hearts.
reated mouse hearts showed normal longitudinal conduc-
ion velocities. Transverse conduction velocity was not
ltered (Fig. 4, Table 2).
educed phosphorylation of Cx43 in myocardium from
lako/– hearts after training is improved by therapy.
Plakoglobin, -catenin, and plakophilin-II seemed nor-
ally localized in treated and untreated plako/– hearts (12
sections/heart, 3 hearts) (Fig. 5A) (15). The absolute light
intensity of plakoglobin was not different between groups
(12 sections and 1,600 to 2,400 images/group, not shown).
When -catenin was used as reference protein, immuno-
histological plakoglobin light intensity was reduced in
plako/– hearts as expected (plakoglobin/-catenin ratio:
WT 0.64  0.2; plako/– 0.43  0.1; treated plako/– 0.45 
.08, mean  SEM; 12 sections/heart, 3 hearts, 1,600 to
,400 images/group; p  0.01 WT vs. plako/–).
Western blots confirmed reduced plakoglobin expression
in LV homogenates (Fig. 5B), whereas -catenin and
-cadherin concentration was not significantly altered
Fig. 5B). Furthermore, we did not find a significantly
,eained Treated,
lako/– Mice
Plako/– Plako/– Treated
44.0 1.8*† 52.5 2.2
41.4 1.4*† 50.8 1.4
29.5 1.7 30.9 1.8
25.8 1.7 28.8 2.4
35 3 34 3
56.4 3.8 55.7 3.5
28.9 2.4 30.3 1.9
46 3 42 5
34 4 35 5
15/25 (60%)‡§ 5/19 (26%)
2/20 (10%) 1/16 (6%)
ned and trained), trained treated, and trained untreated heterozygous
0.01 versus treated plako/– mice; ‡p 0.05 versus WT; §p 0.05
pacing with fix cycle length, S2  50 ms programmed stimulation
entricular tachycardia; other abbreviations as in Table 1.eatedMicT, Tr
us P
1.3
2.0
1.7
2.6
3
2.8
2.2
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9%)
%)
(untrai
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plako/– hearts (plakoglobin untreated 0.4  0.1, treated
.9 0.5; -catenin untreated 1.6 0.4, treated 2.4 0.6;
mean  SEM; both p  0.2; n  4 to 6/group).
Histological examination of myocardial slices from un-
treated plako/– and WT mice did not reveal abnormalities
Figs. 5A and 6A) (15). Target genes of the wnt signaling
athway were neither differentially expressed in plako/– hearts
(PCR ratio compared with WT: peroxisome proliferator-
activated receptor gamma 1.22; cyclin D1 1.12; collagen 1a
1.41; collagen 3a 1.17) nor in embryonal plako-/- hearts (Day
0 to 11 after conception, PCR ratio compared with WT:
eroxisome proliferator-activated receptor gamma 0.93; cyclin
Figure 4 Pre-Load–Reducing Therapy Prevents Training-Induced
(A) Activation patterns after central stimulation from the right ventricle (RV) and le
heart. Conduction slowing is indicated by closely spaced isochrones. Conduction s
treated plako/– mice. Color scale shows activation time, lines are 1-ms isochron
(hatched bars) direction to the fiber orientation. Longitudinal RV conduction veloci
plako/– mouse hearts after training, both during fix frequent pacing and at prema
mean  SEM. Abbreviations as in Figures 2 and 3.1 0.71; collagen 1a 0.78; collagen 3a 0.73). (Localization of Cx43 at the short ends of cardiomyocytes
as not different between groups (Fig. 6A). Connexin43
oncentration was lower in untreated plako/– hearts than
in WT hearts, and this effect was attenuated in treated
plako/– hearts: Three consecutive Western blots consis-
tently showed a lower level of non-phosphorylated Cx43
and phosphorylated connexin43 (P-Cx43) in untreated
plako/– mice compared with WT hearts (examples in Figs.
B and 6C). The Cx43 and P-Cx43 concentrations were
ignificantly lower in untreated plako/– hearts than in WT,
whereas we found no statistically significant difference
between treated plako/– and WT hearts (Fig. 6D, 3 blots).
ndividual blots showed similar trends in RV myocardium
itudinal RV Conduction Slowing in Plako/– Mouse Hearts
ricle (LV) of a trained WT, an untreated plako/–, and a treated plako/– mouse
was observed in the RV activation maps of trained, untreated but not in trained,
) Mean RV conduction velocities in the longitudinal (open bars) and transversal
reduced in untreated plako/– mice compared with either WT or treated
timulation (S2  50 ms). Number is indicated in the bars. All data given asLong
ft vent
lowing
es. (B
ty was
ture sFig. 6C), albeit with higher intraindividual variability. The
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Figure 5 Localization and Concentration of Cell Adhesion Proteins
(A) Normal localization of area composita proteins at cell–cell interfaces. Shown are immunofluorescence micrographs of RV sections of a WT, an untreated plako/–,
and a treated plako/– mouse heart. The -catenin (green) and plakoglobin (red) localize in area composita junctions at the short cell axes, irrespective of study
group. Both proteins localize in intercalated disk areas in addition to often laterally situated small capillaries. By contrast, plakophilin-2 (red) is restricted to the
intercalated disk regions. (B) Reduced myocardial concentration of plakoglobin but not -catenin or N-cadherin. Shown are mean ( SEM) protein levels in LV
myocardium (left panel) and representative blots of plakoglobin, -catenin, N-cadherin, and the respective GAPDH loading control (right panel). Abbreviations as
in Figures 2 and 3.
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from plako/– mice without VTs compared to plako/–
mice with VTs (Fig. 6E).
Discussion
Main findings. We report for the first time that a therapy
aimed at reducing RV load prevents development of ARVC
in a model with reduced expression of the gene encoding the
mechanical cell–cell contact protein plakoglobin. Therapy
completely prevented the development of RV enlargement
and conduction slowing and normalized inducibility of VTs,
thereby rendering treated plakoglobin-deficient animals
phenotypically indistinguishable from their trained WT
littermates. In untreated animals, conduction slowing was
associated with reduced concentration and phosphorylation
of Cx43. Our data suggest that load reduction could be a
simple and effective way to prevent or slow the development
Figure 6 Reduced Cx43 Concentration in Plako/– Mouse Hea
(A) Connexin43 was normally located in plako/– mouse hearts. (B, C) Represent
tissue. (D) Quantitative comparison of the mean concentration levels of phosphor
ized to the housekeeping protein calnexin and expressed as a fraction of the mea
reduced in untreated plako/– hearts. (E) P-Cx43 concentration in plako/– hearts
without VTs (mean of 1 blot performed specifically to compare hearts with and wit
sus WT; †p  0.05 versus hearts with VTs. F: Bar graph of mean LV Cx43 and P-Cx4of ARVC in genetically susceptible hearts.Training-induced dilation of the RV might confer
ARVC. Endurance training can provoke or accelerate the
development of ARVC or RV arrhythmias (2,22,23,29,31).
Our study suggests that increased RV load during training
periods contributes to the accelerated expression of ARVC
in susceptible persons (e.g., in endurance athletes carrying a
genetic predisposition for the disease).
Therapy prevents RV enlargement and increased Cx43
expression in trained plako/– mice. Conduction slowing
was associated with reduced Cx43 expression in this study,
whereas there were no histo-morphological changes in
affected RVs. Cx43, the main protein that forms gap
junctions and confers electrical coupling between cardiomy-
ocytes, co-localizes with desmosomal proteins in the area
composita region (32). It has been suggested that mechan-
ical dysfunction of cell–cell contacts (e.g., caused by reduced
plakoglobin gene expression) interferes with formation of
gap junctions and reduces electrical cell–cell coupling (33).
Indeed, patients with ARVC might contain less Cx43 at the
estern blot of Cx43 in WT, plako/–, and treated plako/– LV (B) and RV (C)
connexin43 (P-Cx43) and non-phosphorlyated Cx43 (Cx43) in LV tissue normal-
e of untreated plako/– mice (mean of 3 blots). Both P-Cx43 and Cx43 were
nd without VT. P-Cx43 concentration was lower in plako/– hearts with than
T). Columns show mean  SEM; n is indicated in the columns; *p  0.05 ver-
ession levels in the 3 study groups. Abbreviations as in Figures 2 and 3.rts
ative W
ylated
n valu
with a
hout V
3 exprmyocardial intercalated disks (4,33). Our study provides
c
i
s
D
p
o
g
b
n
p
t
m
e
e
m
c
R
e
m
749JACC Vol. 57, No. 6, 2011 Fabritz et al.
February 8, 2011:740–50 Load-Reducing Therapy Prevents ARVCfurther support of this hypothesis: training dilated the RV,
provoked arrhythmias, and reduced Cx43 content in
plako/– hearts. It is conceivable that reduced mechanical
ontacts between cells resulted in lesser binding of connex-
ns to the cell–cell contacts, thereby promoting conduction
lowing.
ecreased myocardial plakoglobin in ARVC. Myocardial
lakoglobin content might be a sensitive and specific marker
f ARVC in patients (4). Reduced concentration of plako-
lobin with normal localization was confirmed by Western
lots and immunohistology in this study, although we did
ot identify obvious alterations in -catenin, N-cadherin, or
lakophilin-II. Further studies are warranted to characterize
he composition of cell adhesion complexes in ARVC in
ore detail. Taken together with published clinical (4) and
xperimental findings (15), our study supports the hypoth-
sis that reduced myocardial plakoglobin concentration
ight constitute a key component and possibly a “final
ommon pathway” in the development of ARVC.
educed concentration and phosphorylation of Cx43
xplains longitudinal conduction slowing in plako/–
hearts. Although statistically robust, the observed changes
in conduction velocity were modest. However, the combi-
nation of reduced conduction velocity and increased RV and
LV size enhances the arrhythmogenic substrate for re-entry.
Transverse conduction velocity was not altered in plako/–
hearts in this study, possibly because gap junctions are prefer-
entially expressed in the longitudinal interfaces of myocardial
fibers (Fig. 6A) (26). The observed longitudinal conduction
delay will cause conduction heterogeneity and can thereby
explain functional reentry and induction of ventricular arrhyth-
mias (Fig. 3) in untreated plako/– hearts.
ARVC develops without activation of the wnt pathway in
this model. Unlike observations in most but not all (33)
patients with ARVC, fibro-fatty replacement of RV myo-
cardium is not found in plakoglobin-deficient mice, and
gene expression is not different from WT tissue in affected
hearts (Fig. 2A in Kirchhof et al. [15]). These surprising
observations led to a speculation that fibro-fatty replace-
ment could be a prominent but not a required finding in
ARVC (15), possibly driven by nuclear translocation of
plakoglobin and suppression of the wnt signaling pathway
(16)—which might occur when mutations in desmoplakin
or desmoglein reduce desmosmal binding of plakoglobin
but not when plakoglobin is reduced generally, as in the
present model. In line with this hypothesis, we did not find
alterations of wnt signaling in plakoglobin-deficient mice.
Study limitations. We did not investigate whether load-
reducing therapy has beneficial effects when ARVC has
already developed or whether such a therapy has effects
when fibro-fatty replacement is present. Therapy-induced
increased myocardial Cx43 concentration and phosphoryla-
tion might suggest an effect on electrical conduction even in
such conditions, but this requires further study. Although
reduced expression of plakoglobin appears as a specific and
sensitive molecular change in ARVC patients (4), thefindings of this experimental study require confirmation in
other models and in patients.
Conclusions
Load-reducing therapy consisting of furosemide and ni-
trates completely prevents the development of an ARVC-
phenotype in heterozygous plakoglobin-deficient mice. Our
data invite further validation of such an intervention in
other models of ARVC and in patients.
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